S. 920 

One Hundred Fifteenth Congress 

of the 

United States of America 

AT THE FIRST SESSION 

Begun and held at the City of Washington on Tuesday, 

the third day of January, two thousand and seventeen 

An Act 

To establish a National Clinical Care Commission. 

Be it enacted by the Senate and House of Representatives of 

the United States of America in Congress assembled, 

SECTION 1. SHORT TITLE. 

This Act may be cited as the ‘‘National Clinical Care Commission Act’’. 

SEC. 2. NATIONAL CLINICAL CARE COMMISSION. 

(a) ESTABLISHMENT.—There is hereby established, within the 

Department of Health and Human Services, a National Clinical 

Care Commission (in this section referred to as the ‘‘Commission’’) 

to evaluate and make recommendations regarding improvements 

to the coordination and leveraging of programs within the Department and other Federal agencies related to awareness and clinical 

care for at least one, but not more than two, complex metabolic 

or autoimmune diseases resulting from issues related to insulin 

that represent a significant disease burden in the United States, 

which may include complications due to such diseases. 

(b) MEMBERSHIP.— (1) IN GENERAL.—The Commission shall be composed of 

the following voting members: 

(A) The heads of the following Federal agencies and 

departments, or their designees: 

(i) The Centers for Medicare & Medicaid Services. 

(ii) The Agency for Healthcare Research and 

Quality. 

(iii) The Centers for Disease Control and Prevention. 

(iv) The Indian Health Service. 

(v) The Department of Veterans Affairs. 

(vi) The National Institutes of Health. 

(vii) The Food and Drug Administration. 

(viii) The Health Resources and Services Administration. 

(ix) The Department of Defense. 

(x) The Department of Agriculture. 

(xi) The Office of Minority Health. 

(B) Twelve additional voting members appointed under 

paragraph (2). 

(2) ADDITIONAL MEMBERS.—The Commission shall include 

additional voting members, as may be appointed by the Secretary, with expertise in the prevention, care, and epidemiology 

of any of the diseases and complications described in subsection 
S. 920—2 

(a), including one or more such members from each of the 

following categories: 

(A) Physician specialties, including clinical 

endocrinologists, that play a role in the prevention or treatment of diseases and complications described in subsection 

(a). 

(B) Primary care physicians. 

(C) Non-physician health care professionals. 

(D) Patient advocates. 

(E) National experts, including public health experts, 

in the duties listed under subsection (c). 

(F) Health care providers furnishing services to a 

patient population that consists of a high percentage (as 

specified by the Secretary) of individuals who are enrolled 

in a State plan under title XIX of the Social Security 

Act or who are not covered under a health plan or health 

insurance coverage. 

(3) CHAIRPERSON.—The members of the Commission shall 

select a chairperson from the members appointed under paragraph (2). 

(4) MEETINGS.—The Commission shall meet at least twice, 

and not more than four times, a year. 

(5) VACANCIES.—A vacancy on the Commission shall be 

filled in the same manner as the original appointments. 

(c) DUTIES.—The Commission shall evaluate and make recommendations, as appropriate, to the Secretary of Health and 

Human Services and Congress regarding— 

(1) Federal programs of the Department of Health and 

Human Services that focus on preventing and reducing the 

incidence of the diseases and complications described in subsection (a); 

(2) current activities and gaps in Federal efforts to support 

clinicians in providing integrated, high-quality care to individuals with the diseases and complications described in subsection 

(a); 

(3) the improvement in, and improved coordination of, Federal education and awareness activities related to the prevention and treatment of the diseases and complications described 

in subsection (a), which may include the utilization of new 

and existing technologies; 

(4) methods for outreach and dissemination of education 

and awareness materials that— 

(A) address the diseases and complications described 

in subsection (a); 

(B) are funded by the Federal Government; and 

(C) are intended for health care professionals and the 

public; and 

(5) whether there are opportunities for consolidation of 

inappropriately overlapping or duplicative Federal programs 

related to the diseases and complications described in subsection (a). 

(d) OPERATING PLAN.—Not later than 90 days after its first 

meeting, the Commission shall submit to the Secretary of Health 

and Human Services and the Congress an operating plan for carrying out the activities of the Commission as described in subsection 

(c). Such operating plan may include— 
S. 920—3 

(1) a list of specific activities that the Commission plans 

to conduct for purposes of carrying out the duties described 

in each of the paragraphs in subsection (c); 

(2) a plan for completing the activities; 

(3) a list of members of the Commission and other individuals who are not members of the Commission who will need 

to be involved to conduct such activities; 

(4) an explanation of Federal agency involvement and 

coordination needed to conduct such activities; 

(5) a budget for conducting such activities; and 

(6) other information that the Commission deems appropriate. 

(e) FINAL REPORT.—By not later than 3 years after the date 

of the Commission’s first meeting, the Commission shall submit 

to the Secretary of Health and Human Services and the Congress 

a final report containing all of the findings and recommendations 

required by this section. 

(f) SUNSET.—The Commission shall terminate 60 days after 

submitting its final report, but not later than the end of fiscal 

year 2021. 

Speaker of the House of Representatives. 

Vice President of the United States and

President of the Senate.